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Abstract
Introduction: Viral remission after analytical treatment interruption (ATI), termed post-treatment control, has been described
in a small proportion of HIV-positive patients. This phenomenon has been separately associated to both low levels of HIV-1
proviral DNA as well as cell-associated RNA. We investigated whether the combination of both parameters could help predict
delayed viral rebound after treatment interruption (TI).
Methods: We conducted an open single-arm ATI study in four Belgian HIV reference centres from January 2016 to July
2018. Eligible participants were adults who had fewer than 50 HIV-1 RNA copies/mL for more than two years, more than
500 CD4 cells/µL for more than three months, and were in general good health. Consenting participants who had fewer than
66 copies total HIV-1 DNA (t-DNA) and fewer than 10 copies cell-associated HIV-1 unspliced RNA (US-RNA) per million
peripheral blood mononuclear cells (PBMCs), interrupted therapy and were monitored closely. Antiretroviral therapy (ART)
was resumed after two consecutive viral loads exceeding 1000 copies or one exceeding 10,000 copies/mL. The primary out-
come was the proportion of participants with fewer than 50 HIV-1 RNA copies/mL 48 weeks after TI. Secondary outcomes
were time to viral rebound, the frequency of serious adverse events (AEs) and evolution of t-DNA and US-RNA after TI.
Results: All 16 consenting participants who interrupted therapy experienced rapid viral rebound two to eight weeks after TI.
No serious AEs were observed. Levels of t-DNA and US-RNA increased after TI but returned to pre-ATI levels after treatment
restart. None of the studied demographic, clinical and biological parameters were predictive of time of viral rebound.
Conclusions: The combination of low levels of t-DNA and US-RNA in PBMCs, corresponding respectively to a small and tran-
scriptionally silent viral reservoir, is not predictive of viral remission after TI in patients on ART.
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1 | INTRODUCTION
Although antiretroviral therapy (ART) effectively blocks HIV
replication, HIV persists in a reservoir of latently infected
CD4+ T cells [1]. This causes most patients to experience viral
rebound within weeks after treatment interruption [2]. Viral
remission after analytical treatment interruption (ATI), termed
post-treatment control (PTC), has been described in a small
proportion of patients [3–5]. Although PTC has been associ-
ated with early treatment initiation [6], we and others showed
that some PTCs initiated ART in the chronic phase [4,7]. A
single common characteristic of all well-documented PTCs is
the presence of a very small reservoir similar to “elite” con-
trollers [8–12].
Besides the size of the viral reservoir (measured as total
HIV-1 cell-associated DNA or t-DNA), its transcriptional activ-
ity (measured as HIV-1 cell-associated unspliced RNA or US-
RNA) also independently correlates with the delay of viral
rebound after ATI [9,11,13]. Indeed, a pooled analysis of six
AIDS Clinical Trials Group ATI studies aiming at identifying
predictors of viral rebound, revealed that higher levels of US-
RNA are associated with shorter time to viral rebound (TTVR)
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after ATI [11]. However, no prospective studies have investi-
gated the association between TTVR and the combination of a
very small latent viral reservoir (t-DNA) and minimal on-going
viral transcription (US-RNA) before ATI.
We therefore designed a single-arm open ATI trial where
patients on ART were selected based on both low levels of t-
DNA and US-RNA. The aim of the study was to evaluate
whether these combined selection criteria could help to better
predict delayed viral rebound.
The primary objective of this study was to determine the
proportion of participants with plasma viral load (pVL) < 50
copies/mL at 48 weeks after ATI. Secondary objectives
included a safety assessment of the ATI, TTVR, kinetics of pVL
as well as evolution of viral reservoir t-DNA and US-RNA dur-
ing ATI and after restarting ART. Exploratory objectives
included the identification of other potential factors predictive
of TTVR, such as demographic, clinical and biological parame-
ters, including CD4+ T cell nadir, ultrasensitive plasma viral
load (usVL) [14], integrated DNA and HIV-1 cell-associated
long terminal repeat (LTR)-RNA levels [15] as well as in vitro
assays for viral RNA release [16] and infectious viral out-
growth [17]. Finally, we investigated the origin of rebound
viruses by comparing in vivo rebound with in vitro outgrowth
viruses by single genome analysis (SGA).
2 | METHODS
2.1 | Study design and participants
The study ran from 25 January 2016 to 22 July 2018. In the
first stage, 114 consenting individuals were recruited from a
total patient population of 7212 HIV-1–positive people on ART
from four major Belgian HIV Reference Centers: one in
Antwerp (Institute of Tropical Medicine (ITM)), two in Brussels
(University Medical Center (UMC) and Universitair Ziekenhuis
Brussel (UZB)) and one in Ghent (Universitair Ziekenhuis Gent
(UZG)). Inclusion criteria included nadir CD4+ T-cell count
>300 cells/µL, current CD4+ T-cell count ≥500 cells/µL for
≥3 months and pVL < 50 copies/mL for ≥2 years. Exclusion cri-
teria included, among others, pregnancy, breastfeeding, active
hepatitis B or C infection and any psychiatric or psychological
disorder that could interfere with participation in an ATI study.
Stage 1 participants were screened for t-DNA and US-RNA
levels. Participants with t-DNA < 66 copies per million periph-
eral blood mononuclear cells (PBMCs) and US-RNA < 10
copies per million PBMCs were eligible for stage 2. We have
not included a control arm of participants with a high viral
reservoir mainly for futility and safety reasons. The threshold
for t-DNA was based on the DNA levels from a previous clini-
cal study [18]. The 15th percentile of the cohort was used as
a threshold to include only patients with a small reservoir. The
threshold for US-RNA corresponded to the limit of detection
of the assay when performed in three replicate reactions.
Consenting participants eligible for stage 2 were psychologi-
cally examined to evaluate their motivation for participation
and to avoid potential misconceptions on study objectives
[19]. A leukapheresis was performed and ART was interrupted
(baseline) after sexual counselling. Participants were followed
for 48 weeks or until ART resumption criteria were reached.
In line with other treatment interruption studies [5], these cri-
teria included two consecutive viral loads >1000 copies/mL
measured at least three days apart, a single viral load
>10,000 copies/mL, CD4+ T-cell count drop to <350 cells/µL
at two consecutive measurements at least two weeks apart or
a drop of more than 50% compared to baseline, any new sig-
nificant clinical condition, a new sexually transmitted infection,
pregnancy or participant withdrawal from the study.
On weeks 2/4/6/8/12/16/20/24/32/40/48 post ATI as well
as week 4 and 12 post ART restart, whole blood was collected
for plasma and PBMC separation (Figure 1a). Plasma was
used for immediate pVL measurement and the remainder was
stored at 80°C. All PBMCs were stored in liquid nitrogen.
2.2 | Ethics statement
The study was approved by the internal review board of the
ITM in Antwerp, the ethics committees of the University
Hospitals of Antwerp (UZA), Ghent (UZG) and Brussels (UMC
St. Pierre, UZB) (respective approval numbers: 1012/15, 15/
31/321, 2015/0771, AK/15-07-84/4539 and 2015/261) and
was registered on clinicaltrials.gov with the number
NCT02590354.
2.3 | Safety assessments
Safety assessments were performed at each study visit and
included evaluation of clinical signs as well as laboratory
parameters. The severity of adverse events (AEs) was scored
according to the Division of AIDS toxicity table [20].
2.4 | Cell-associated HIV-1 DNA and RNA
measurements
At screening, t-DNA and US-RNA were measured by droplet
digital polymerase chain reaction. Subsequently, in the
selected stage 2 participants, the following HIV-1 measure-
ments were performed: t-DNA and cell-associated LTR HIV-1
RNA (LTR-RNA) in PBMCs at baseline, weeks 2/4/6/8/12/16/
20/24/32/40/48 post-ATI, and week 12 post-ART restart
(PW12); integrated HIV-1 DNA in PBMCs at baseline, before
ART restart and PW12; LTR-RNA in CD4+ T cells at baseline
(Figure 1a). US-RNA targets the gag/pol region and repre-
sents a late complete transcript, whereas LTR-RNA targets
the 50-LTR region, representing the earliest incomplete tran-
script [15,21]. For technical details see Methods S1.
2.5 | Ultra-sensitive pVL
Ultrasensitive pVL was measured as described by Leal et al.
with minor modifications [14]. In short, 10 mL of EDTA
plasma was concentrated to 0.8 mL by ultracentrifugation at
170,0009 g for one hour in a swinging bucket rotor (Beck-
man Coulter, Brea, CA, USA) and tested on the Roche Cobas
4800 system. usVL results were multiplied by 0.08 (0.8/10) to
account for the concentration. The assay can reliably detect
viral loads ≥5 copies/mL.
2.6 | Quantitative viral outgrowth assay
The quantitative viral outgrowth assay (qVOA) was performed
on 24 9 106 CD4+ T cells as described by Laird et al. with
some modifications [17]. For technical details see Methods S2.
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2.7 | Viral release assay
The viral release assay (VRA) was performed as described by
Cillo et al. with minor modifications [16]. PBMCs and CD4+ T
cells were cultured in unstimulating and stimulating conditions.
The unstimulated condition refers to overnight resting in Ros-
well Park Memorial Institute 10% fetal calf serum + 0.6%
penicillin/streptomycin + 100 nmol/L Dapivirine + 100 nmol/L
Raltegravir. For the stimulated condition, cells were incubated
for seven days in the same complete medium with additional
50 ng/mL phorbol myristate acetate (Sigma, Diegem, Belgium)
and 500 ng/mL ionomycin (Sigma). PBMCs were plated in six-
well plates at 15 9 106 cells per well in 5 mL medium. CD4+
T cells were plated in 24-well plates at 5 9 106 cells per well
in 2.5 mL medium. Supernatant was stored at 80°C until
assessment of virus release by quantitative real-time PCR
with the commercial COBAS HIV-1 viral load test (Roche,
Basel, Switzerland).
2.8 | SGA comparing viruses from qVOA and
rebound plasma
Supernatant from TZM-Bl-positive qVOA wells from three
participants (1011, 4012 and 3033) with more than two posi-
tive qVOA wells (resp. 13, 11 and 3 wells) was harvested and
10 µL was subjected to RNA extraction using the QIAamp
mini viral RNA kit (Quiagen, Venlo, The Netherlands), accord-
ing to the manufacturer’s instructions. Viral RNA was
extracted from plasma samples at the time of rebound, as
described previously [22]. Subsequently, cDNA was generated
using the Superscript III RT kit (Invitrogen, Carlsbad, CA,
USA), according to the manufacturer’s instructions. In the case
of rebound samples, a dilution series (1:3 to 1:243) of the
cDNA was made, aiming for ≤30% positive reactions, and the
V1-V3 env region (894 bp) was amplified using a nested PCR,
as described previously [23]. For qVOA samples, five repli-
cates of the same nested PCR were performed on bulk cDNA,
to ensure the presence of only a single virus per positive well.
Positivity of reactions was checked on a 1% agarose gel, and
amplicons were sequenced from both ends by Sanger
sequencing, using second round primers.
2.9 | Phylogenetic analyses
Phylogenetic analyses on V1-V3 sequences derived from
qVOA wells and plasma were performed as described previ-
ously [23,24]. Sequences that did not meet quality standards
and hypermutated sequences were omitted from further anal-
ysis. The remaining sequences were used to construct contigs,
which were aligned with MUSCLE [25]. In the case of qVOA
sequences, the five replicate contigs per positive well were
multiple aligned and the consensus sequence was extracted.
Maximum likelihood phylogenetic trees were constructed with
PhyML v3.1 [26], using the general time-reversible nucleotide
substitution model with 1000 bootstraps. Additionally, a neigh-
bour-joining tree with all sequences from the three subjects
was created to check for inter-sample contamination.
2.10 | Statistical analysis
Categorical data are presented as frequency counts and per-
centages, and continuous variables are presented as medians
and interquartile ranges. Continuous measurements were
compared using the Wilcoxon signed-rank and Mann-Whitney
test in the case of dependent and independent samples
respectively. Spearman’s rank correlation coefficients were
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Figure 1. (a) Overview of stage 1 and 2 of the study. Timepoints at which blood was drawn for plasma and PBMC separation are indicated with
yellow arrows. ART is restarted when treatment resumption criteria are reached or 48 weeks after treatment interruption. (b) t-DNA values in
copies per million PBMCs for all stage 1 participants. Participants with t-DNA values >66 copies per million PBMCs are indicated with grey dots
(n = 75). Patients with t-DNA values below 66 copies but US-RNA values above 10 copies per million PBMCs are indicated with green dots
(n = 3). Patients with t-DNA and US-RNA values below 66 and 10 copies per million PBMCs respectively are indicated with blue dots (n = 38)
and are eligible for stage 2 participation. (c) Flow chart with number of patients screened until number of patients who completed the study. ART,
antiretroviral therapy; ATI, analytical treatment interruption; PBMC, peripheral blood mononuclear cell; pVL, plasma viral load; t-DNA, total HIV-1
DNA; US-RNA, cell-associated HIV-1 unspliced RNA.
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calculated to determine correlations between VRA and US-
RNA results. To analyse virological markers over time a Fried-
man Rank Sum test, followed by a post-hoc Nemenyi test for
unreplicated blocked data, was performed on participant sam-
ples without missing data for baseline, timepoint before
restart ART and 12 weeks post-ATI. Cox proportional hazard
models were used to calculate the probability of viral rebound
at each time point and to assess associations of clinical, viro-
logical and immunological parameters with TTVR dynamics.
3 | RESULTS
3.1 | Participant selection and clinical
characteristics
In stage 1, 114 patients who provided written informed con-
sent were recruited (characteristics in Table S1). Median t-
DNA and US-RNA levels were 107 [inter quartile range, IQR:
46 to 205] and 3.0 [IQR: 1.0 to 6.0] copies per million PBMCs
respectively. Forty-one (36.0%) had t-DNA levels <66 copies
per million PBMCs. Of those, 38 (92.7%) also had US-RNA
levels <10 copies per million PBMCs and were therefore eligi-
ble for treatment interruption (Figure 1b). Twenty-two did not
consent or were excluded for participation in stage 2 for vari-
ous reasons (Figure 1c). The 16 remaining stage 2 participants
included 15 men and one woman with median age 44 years
[IQR: 38 to 54], median time on ART 4.0 years [IQR: 2.9 to
6.2] and median CD4+ T-cell count 758 cells/µL [IQR: 679 to
845]. Time since diagnosis was significantly shorter in the 16
patients who participated in stage 2 (median [IQR]: 3.9 years
[2.8 to 6.3]) as compared to the patients who were not eligi-
ble for stage 2 (median [IQR]: 6.2 years [4.0 to 9.6]). Detailed
participant characteristics are given in Table 1.
3.2 | Treatment interruption with close follow-up is
safe
ATI was generally safe as no serious AEs were recorded. How-
ever, most participants (13/16; 81%) reported an AE, with a
total of 32 AEs recorded. All AEs were mild or moderate in
intensity and resolved by the end of the study period. No side
effects specifically related to the leukapheresis were reported.
Three AEs (in three participants, 18.8%) were deemed to be
related to the treatment interruption, occurred around the
time of viral rebound and resolved spontaneously (Table S2).
These may have contributed to the decision to restart ART.
3.3 | Rapid viral rebound following treatment
interruption, complete resuppression of viraemia and
normalization of reservoir measures after treatment
restart
All participants experienced viral rebound between two and
eight weeks post ATI (Figures 2a and S1). All but one partici-
pant resumed ART immediately after reaching viral rebound
criteria. Participant 4012 reached rebound criteria by week 8
but maintained pVLs < 3500 copies/mL until week 11, when
ART was restarted. By 12 weeks after ART restart, all partici-
pants in follow-up suppressed viraemia again below 50 copies/
mL. Two participants were lost to follow-up after treatment
restart. One restarted treatment shortly after the viral
rebound and returned to follow-up 11 months later with an
undetectable viral load. The other one had had an unde-
tectable viral load four weeks after restart but moved to
another country afterwards.
Total and integrated DNA and LTR-RNA were determined
before and during ATI as well as after restart of ART on bulk
PBMCs (Figures 2b,c,d and S1). At the time-point before ART
resumption, total and integrated DNA as well as LTR-RNA
were significantly higher as compared to baseline (p < 0.0001,
<0.05 and <0.05 respectively). By week 12 post ART resump-
tion, integrated DNA and LTR-RNA normalized to baseline
levels, while t-DNA remained slightly but non-significantly
higher than baseline (p > 0.05).
3.4 | TTVR is not associated with residual viraemia,
in vitro viral release, qVOA and LTR-RNA levels
Clinical parameters such as HIV risk group, treatment regi-
men, time on treatment, nadir and current CD4+ T-cell count
were not associated with TTVR. To further characterize the
16 strictly selected stage 2 participants, we measured addi-
tional viral parameters at baseline, including residual viraemia
(usVL), in vitro viral outgrowth, in vitro viral release and LTR-
RNA levels in CD4+ T cells before ATI.
Only one of the selected participants had a pVL > 5 copies/
mL (5.9 copies/mL) while on ART; nine had a detectable
pVL < 5 copies/mL and five had undetectable pVLs (Figure 3a).
Plasma from one participant (2025) was not available for test-
ing. There was no association between residual viraemia and
TTVR (Figure S5).
In the qVOA assay, very low replication competent fractions
were observed in the participants, with a median of 0.042
infectious units per million cells [IQR: 0.032 to 0.085] (Fig-
ure 3b). Again, there was no association between the size of
Table 1. Individual characteristics of stage 2 study participants
(n = 16)
Study
ID
Time on ART
(years)
Time with undetectable
pVL (years)
CD4 nadir
(cells/µL)
1011 3.2 2.9 446
1029 3.0 2.8 661
1038 4.7 4.2 379
1043 6.9 3.4 435
1044 11.4 7.1 328
2007 2.6 2.5 506
2022 2.6 2.5 302
2025 6.4 5.5 402
3024 15.6 8.5 467
3033 7.8 6.8 319
3034 3.0 2.4 356
4002 4.3 4.0 454
4006 3.5 3.1 495
4010 2.7 2.6 554
4012 4.7 4.4 303
4018 3.7 3.4 573
ART, antiretroviral therapy; pVL, plasma viral load.
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the replication competent fraction and TTVR. To further dis-
tinguish the selected participants based on transcriptional
activity, LTR-RNA measurements were repeated at baseline in
enriched CD4+ T cells instead of bulk PBMCs. As opposed to
US-RNA in PBMCs, LTR-RNA in CD4+ T cells was always
detectable and ranged from 6.5 to 744.6 copies per million
CD4+ T cells (median: 105.4 copies) but was not associated
with TTVR (Figure S2).
Finally, the recently described VRA was performed. Sponta-
neous viral release from PBMCs was significantly lower in
stage 2 participants as compared to a selection of 12 stage 1
participants with the highest t-DNA levels (median 441 copies
per million PBMCs) (Figure S3). Significantly larger amounts of
virus were spontaneously released per million CD4+ T cells as
compared to PBMCs (median 1.00 vs. 0.22 log copies/mL,
p < 0.05) as well as with stimulated versus non-stimulated
PBMCs (median 1.77 vs. 0.22 log copies/mL, p < 0.001) (Fig-
ure 3c,d). Nevertheless, TTVR was not associated with sponta-
neous or stimulated viral release in PBMCs or CD4+ T cells.
Interestingly, at baseline, the level of LTR-RNA in CD4+ T
cells significantly correlated with the amount of viral RNA
released in the supernatant of PBMC or CD4+ T cells with or
without stimulation as measured in the VRA assay (Figure S4).
Clustering of rebound sequences and in vitro viral out-
growth sequences indicates close relatedness and potential
value of qVOA To examine the relationship between in vivo
viral rebound and in vitro viral outgrowth viruses, V1-V3 env
sequences obtained by SGA were compared between plasma
rebound viruses and qVOA viruses at baseline in the three
participants with more than two positive qVOA wells (1011,
4012 and 3033). A total of 125 plasma rebound sequences
were compared to 24 sequences obtained from qVOA.
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Figure 2. (a) Plasma viral rebound dynamics after ATI until ART restart in 16 selected patients with very small viral reservoir, (b, c, d) dynamics
of total and integrated HIV-1 DNA and LTR HIV-1 CA-RNA over time in stage 2 patients. p-Values are from Friedman Rank Sum tests and post-
hoc Nemenyi test. ART, antiretroviral therapy; ATI, analytical treatment interruption; LTR, long terminal repeat; PBMC, peripheral blood mononu-
clear cell; PW12: 12 weeks after restart ART; VR, timepoint at viral rebound just before restart ART, W, weeks; W0, timepoint at stop ART.
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Rebound and qVOA sequences phylogenetically clustered
together for each participant (Figure S5). When analysing the
individual maximum likelihood phylogenetic tree (Figure 4), no
identical sequences were found between rebound and qVOA
viruses for two participants (4012 and 3034), although all
sequences intermingled and were phylogenetically closely
related. In contrast, in participant 1011, all 12 qVOA viruses
were also found in the rebound plasma and clustered together
in three distinct but closely related clusters.
To estimate the probability that identical viruses in the V1-
V3 env region truly represent viral clones, the clonal predic-
tion score described by Laskey et al. 2016 was calculated
[27]. For the V1-V3 env region, this score is 88.95 (SD
15.605), giving 89% chance that two or more viruses are
identical over the entire genome if they are identical in the
V1-V3 env region, based on 45 publicly available unique
detectable full-genome sequences derived from qVOAs and
rebound plasma.
(a) (b)
(d)(c)
Figure 3. Additional viral parameters before ATI.
(a) Ultra‐sensitive plasma viral load (in HIV‐1 RNA copies/mL). (b) Replication competent fraction (in infectious units per million CD4+ T cells,
IUPM). (c, d) Viral release from 15 × 106 PBMCs (c) and 5 × 106 CD4+ T cells (d), either spontaneous or after stimulation with PMA + ionomycin
(in log copies/mL). p Values are from Wilcoxon matched‐pairs signed‐rank test. ATI, analytical treatment interruption; PBMC, peripheral blood
mononuclear cell.
0.001344
0.001307189
0.00127226
4012 3034 1011
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Figure 4. Maximum likelihood phylogenetic trees of V1-V3 env sequences from rebound plasma and positive quantitative viral outgrowth
assay wells (outgrowth) for participants 4012, 3034 and 1011.
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4 | DISCUSSION
In this study, we hypothesized that ART treated HIV-infected
individuals selected for both very low t-DNA and US-RNA,
would have a delayed viral rebound after interrupting ART.
However, all 16 selected participants rebounded within eight
weeks after ATI, which is similar to what has been observed
in other ATI studies using less stringent criteria [28,29]. In line
with most ATI studies, however, no major AEs were recorded
and all reservoir measures returned to baseline after treat-
ment restart [5,28,30].
It is important to consider that most patients (93%) with
below-threshold levels of t-DNA also had below-threshold
levels of US-RNA. Consequently, participants undergoing ATI
were primarily selected on reservoir size and less so on tran-
scriptional activity. The rapid viral rebound observed in this
study is therefore consistent with a recently published ATI
study which included patients selected on only small reservoir
size, and observed viral rebound in nine of ten patients within
four weeks (eight patients) and 12 weeks (one patient) while
just one patient maintained pVL below 400 copies/mL for
56 weeks [28].
Exploratory objectives included an association analysis
between TTVR and demographic, clinical and biological param-
eters. No correlations were observed between these parame-
ters and TTVR. In view of these results, we decided post-hoc
to quantify on-going viral transcription by LTR-RNA at base-
line as a measure of transcription initiation as opposed to
transcription completion (US-RNA). As recently observed by
Yukl et al. [21], LTR-RNA levels were much higher than US-
RNA levels (Figure S2). Interestingly, LTR-RNA levels corre-
lated significantly with the amount of virus released in in vitro
culture (VRA) but were not associated to TTVR. While the
clinical relevance of these markers of early transcription is
unclear, they are far more sensitive than US-RNA. Future ATI
studies could therefore consider using such markers to select
potential study participants.
To investigate the origin of viral rebound, we compared
qVOA outgrowth viruses with in vivo plasma rebound viruses
using SGA. Exact matches between qVOA and rebound clones
have been reported only very rarely [31,32]. In these three
participants, we observe intermingling between the viral
sequences obtained from qVOA and plasma at viral rebound,
confirming their close phylogenetic relatedness. Interestingly,
in one participant, three distinct viral sequence expansions
from the qVOA had exact matches with sequence expansions
observed in the V1-V3 env rebound sequences. To further
investigate whether viral outgrowth assays have a predictive
value for viral rebound in particular cases more research
needs to be done, including more participants.
This study had a number of limitations. First, we achieved
only half of the sample size which we aimed for at the onset
of the study (16 instead of 32 stage two participants). Assum-
ing a proportion of 5% to 10% of PTCs in our participants,
this smaller sample size increased the possibility of not finding
any PTC from 5% to 18%. Second, all participants experienced
viral rebound within a relatively short time frame, making dif-
ferences in TTVR very small (0 to 6 weeks) and correlations
unlikely, considering the small sample size. Third, participants
were monitored only every other week. More frequent sam-
pling (e.g. twice weekly) could have allowed a more refined
analysis of rebound kinetics and more powerful correlation
analyses. A fourth limitation, inherent to all recent HIV ATI
studies, is that ART was generally restarted immediately or
shortly after meeting the stringent viral rebound criteria. This
may have prevented the detection of viral control after a tran-
sient viral rebound, as is observed in a large subset of PTCs
as late as 24 weeks after ATI [6]. Indeed, one participant
experienced viral rebound after eight weeks but maintained
pVLs below 3500 copies/mL for 11 weeks, after which the
participant decided to restart therapy. Considering the good
safety observed in recent ATI studies [24], and the lower
probability of missing PTCs [6], future trials might consider
adopting higher treatment restart thresholds. These advan-
tages have to be weighed against the risk of exposing partici-
pants and their partners to longer periods of detectable viral
loads and subsequent risk of transmission [33]. Concerning
the comparison between qVOA and rebound sequences, SGS
was limited to the highly variable but relatively small V1-V3
sub-genomic region of env. While longer length SGA sequenc-
ing from positive VOA wells is feasible, this may prove to be
more challenging for rebound plasma virus. Furthermore,
sequencing the entire env gene would increase the clonal pre-
diction score only slightly. The clonal prediction score of this
amplicon is 89%, leaving an 11% chance that the matching
viruses differ in one or more nucleotides somewhere else in
the genome. However, this prediction score was calculated
based on a limited database of 45 unique detectable
sequences and therefore has a high standard deviation, mak-
ing it difficult to interpret this score.
There remains quite some discussion about the value of
qVOA when investigating the HIV reservoir, due to rather
poor correlations with rebound sequences as described here
and by others [34–36]. One potential explanation is that
qVOA is limited to the blood compartment and does not take
into account rebound coming from other anatomical reser-
voirs. As shown by De Scheerder et al. rebound is heteroge-
neous and can be fuelled by any infected cell in any
anatomical reservoir, making it difficult to have an in vitro
proxy [37]. Another potential explanation is the dynamic nat-
ure of the viral reservoir, which implicates that sequences
between different time points and the observed clones might
wax and wane [36,38].
5 | CONCLUSIONS
Although HIV-1 reservoir markers such as t-DNA and US-RNA
have been correlated with PTC status, we show here that their
predictive power is too weak to prospectively identify PTCs
from the general patient population on ART. PTC status most
likely depends not only on the size, transcriptional activity and
replication competence of the viral reservoir in the peripheral
blood, but also on reservoirs elsewhere and the immune activity
in the body. Developing reliable and easy assays to evaluate
whole body parameters of viral activity and immune control
remains a major challenge for HIV cure research.
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